<code id='86242AB65E'></code><style id='86242AB65E'></style>
    • <acronym id='86242AB65E'></acronym>
      <center id='86242AB65E'><center id='86242AB65E'><tfoot id='86242AB65E'></tfoot></center><abbr id='86242AB65E'><dir id='86242AB65E'><tfoot id='86242AB65E'></tfoot><noframes id='86242AB65E'>

    • <optgroup id='86242AB65E'><strike id='86242AB65E'><sup id='86242AB65E'></sup></strike><code id='86242AB65E'></code></optgroup>
        1. <b id='86242AB65E'><label id='86242AB65E'><select id='86242AB65E'><dt id='86242AB65E'><span id='86242AB65E'></span></dt></select></label></b><u id='86242AB65E'></u>
          <i id='86242AB65E'><strike id='86242AB65E'><tt id='86242AB65E'><pre id='86242AB65E'></pre></tt></strike></i>

          knowledge

          knowledge

          author:comprehensive    Page View:4
          Balance innovation
          Medicare laid out in the greatest detail yet how it will choose which drug prices it will negotiate in its brand-new program, and how it will figure out what the government’s opening offer will be. Adobe

          WASHINGTON — Medicare laid out Wednesday in the greatest detail yet how it will choose which drug prices it will negotiate in its brand-new program, and how it will figure out what the government’s opening offer will be.

          Democrats outlined some parts of the process in the Inflation Reduction Act that passed Congress last August, but the details of how drugs will be selected and what factors will be considered have been vague until now. Though the actual negotiated prices won’t take effect for years, Medicare officials must announce the first 10 drugs they’ll negotiate over by Sept. 1.

          advertisement

          The guidance clarifies that the agency will choose the 50 pharmacy drugs that cost Medicare the most money, based on gross expenditures. If drugs have the same cost to the program, then the one that has been approved longer will be ranked higher.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more
          Sarepta Duchenne therapy fails to meet primary endpoint in trial
          Sarepta Duchenne therapy fails to meet primary endpoint in trial

          RubyWallauforSTATSareptaTherapeuticssaidMondayafternoonthatitsgenetherapyforDuchennemusculardystroph

          read more
          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more

          Inari Medical to buy amputation prevention company LimFlow

          Inariwillpay$250millionupfrontand$165moredependingonLimFlow’scommercialsuccess.DavidGregory&Debb